Marc Martin holds a PhD in Neurovirology and Pharmacology from Pierre et Marie Curie University. He began his professional career as a scientific assessor of the virological risks of biologicals and as an expert of the risk of Creutzfeldt-Jakob disease in adhoc EMA expert group.
He was the head of the onco-hematology products assessment Dpt. He set up the early phase clinical trials team and reorganized the early access programs to innovative medicines. He was strongly involved in authorization and innovation policies with a particular attention to favorizing clinical research.
He has over 20 years of experience in the regulation of health products.
Marc MARTIN is the founder of JASM-In, a SME counseling in the development of health innovations. He provides his regulatory and risk management expertise to Healthtech companies and administrations.